Pfizer Corporation

Mesacor, Inc.

David A Perry

Hiroshi Maeda

Junsuke Tone

Mark A Haxell

Christopher J Dutton

Bruce A Lefker

Ravi Shanker Garigipati

George Chang

Paul Picciano

Yasuhiro Kojima

Cheryl M Hayward

Satoshi Nishiyama

H James Harwood

Dongxiang Zeng

Dibenzyl amine compounds and derivatives of Formula I, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans. 

Dibenzyl amine compounds and derivatives

An apparatus to store and facilitate the safe simultaneous use of dumbbells by multiple individuals. The apparatus includes first and second staging stations. The first staging station includes a first side, a second side, and first and second spaced apart towers. An individual can walk from the first side of the staging station to a position between the first and second towers with the individual's entire body in a space intermediate the towers. The second staging station includes a primary side, a secondary side, and spaced apart third tower and fourth towers. The second staging station is positioned normal to the first staging station such that a first individual in the first staging station can grasp dumbbells on an outwardly facing tier of the fourth tower of the second staging station at the same time a second individual is standing between the third and fourth towers of the second staging station.

System and apparatus for storage and use of dumbbells

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

A method to prepare for and conduct an exercise using free weights while minimizing the risk of injury to an individual during the acquisition, use, and return of the free weights includes the step of providing a plurality of cylindrically-shaped free weight plates and a staging station. Each of the free weight plates is mounted on edge in an upright orientation in one of a plurality of detent units of the staging station at a height above the ground. A first one of the free weight plates is manually grasped and rolled from the detent unit onto a horizontally oriented support surface of the staging station, manually removed from the support surface, utilized to perform an exercise, manually returned to the support surface, and manually rolled on the peripheral edge of the first one of the free weight plates from the support surface into one of the detent units.

Method to prepare for and conduct an exercise using free weights

Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.

Acetyl-CoA carboxylase inhibitors

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

PPAR agonists

The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pests, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions comprising such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Process for producing antiparasitic macrolide antibiotics

The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pests, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions containing such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Biologically pure culture of Streptomyces hygroscopicus ATCC 53718

The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pest, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions comprising such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Antiparasitic macrolide antiobiotics

An antibiotic compound of the formula: ##STR1## is an antiparasitic agent active against insect pests, acari, free living nematodes and endo- and ectoparasites. It is prepared by fermentation using the microorganism Streptomyces griseochromogenes ATCC 53928.

Antiparasitic agent

Antiparasitic milbemycin derivatives having at the C.25 position a substituted 2-propenyl group --C(CH.sub.3).dbd.CH--R.sup.2 wherein R.sup.2 is a C.sub.3 -C.sub.8 alkyl, alkenyl or alkynyl group which may optionally contain an oxygen or sulphur atom as part of the chain, or a C.sub.3 -C.sub.8 cycloalkyl or cycloalkenyl group, or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may optionally be substituted by one or more alkyl groups or halogen atoms; and process for their preparation.

Growing community of inventors

New York, NY, United States of America

David A Perry